

COMPANY UPDATE

September 2025

A CMAX SUCCESS STORY!

We're beyond proud to announce a remarkable early-phase clinical trial achievement at CMAX - one that brings fresh hope to patients around the world!

In 2017, our very own Principal Investigator Professor Sepehr Shakib and the dedicated CMAX team conducted the first-ever human trial of NPI-001, a potential new treatment for Retinitis Pigmentosa – a devastating condition that causes progressive vision loss and ultimately, blindness.

That early-phase trial laid the essential groundwork for what has now become a game-changing moment in medical research.

Now, new clinical data reveals that NPI-001 can slow the loss of photoreceptor cells by more than 50% in patients with Retinitis Pigmentosa.

This incredible achievement, recently announced by Nacuity Pharmaceuticals, paves the way for a confirmatory registrational trial in 2026 and offers new hope to individuals and families affected by Retinitis Pigmentosa.

At CMAX, we're proud to know that our work at the very beginning of this journey played a vital role in making this possible. It's moments like these that remind us why early-phase clinical research matters – and how dedicated investigators, volunteers, and clinical teams can help change the future of medicine.

Congratulations to Professor Shakib and the entire CMAX team on being part of this medical advancement.

Another

CMAX SUCCESS STORY!

"After many years, we now have outcome data showing that this drug may help prevent blindness.

This is why we do what we do, and this is our role in helping find cures!"

- Professor Sepehr Shakib

